These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 26506563

  • 21. Comparative Estimates of Crude and Effective Coverage of Measles Immunization in Low-Resource Settings: Findings from Salud Mesoamérica 2015.
    Colson KE, Zúñiga-Brenes P, Ríos-Zertuche D, Conde-Glez CJ, Gagnier MC, Palmisano E, Ranganathan D, Usmanova G, Salvatierra B, Nazar A, Tristao I, Sanchez Monin E, Anderson BW, Haakenstad A, Murphy T, Lim S, Hernandez B, Lozano R, Iriarte E, Mokdad AH.
    PLoS One; 2015; 10(7):e0130697. PubMed ID: 26136239
    [Abstract] [Full Text] [Related]

  • 22. Seroprevalence of antibodies to measles, mumps, and rubella, and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand.
    Chaiwarith R, Praparattanapan J, Nuket K, Kotarathitithum W, Supparatpinyo K.
    BMC Infect Dis; 2016 Apr 30; 16():190. PubMed ID: 27138005
    [Abstract] [Full Text] [Related]

  • 23. [Sero-epidemiologic study of measles, rubella and mumps in the infantile population of Salamanca].
    Sáenz González MC, Núñez Mateos JC, Rodrigo Sánchez N, Martín Sánchez AM.
    An Esp Pediatr; 1992 Apr 30; 36(4):293-7. PubMed ID: 1605414
    [Abstract] [Full Text] [Related]

  • 24. Seroconversion rates following 2 doses of measles- mumps- rubella vaccination given at the ages 12 and 18 months: data for possible additional dose at older age.
    Saffar H, Mousavi SJ, Saffar H, Parsaei MR, Ghorbani GR, Saffar MJ.
    BMC Immunol; 2022 Jan 16; 23(1):2. PubMed ID: 35034609
    [Abstract] [Full Text] [Related]

  • 25. Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age.
    Ceyhan M, Kanra G, Erdem G, Kanra B.
    Vaccine; 2001 Aug 14; 19(31):4473-8. PubMed ID: 11483273
    [Abstract] [Full Text] [Related]

  • 26. MMR vaccination and disease elimination: the Finnish experience.
    Davidkin I, Kontio M, Paunio M, Peltola H.
    Expert Rev Vaccines; 2010 Sep 14; 9(9):1045-53. PubMed ID: 20822347
    [Abstract] [Full Text] [Related]

  • 27. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
    Sultana R, Rahman MM, Hassan Z, Hassan MS.
    Scand J Immunol; 2006 Dec 14; 64(6):684-9. PubMed ID: 17083626
    [Abstract] [Full Text] [Related]

  • 28. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
    Bae GR, Choe YJ, Go UY, Kim YI, Lee JK.
    Vaccine; 2013 May 31; 31(24):2661-6. PubMed ID: 23602654
    [Abstract] [Full Text] [Related]

  • 29. Ethnicity as a correlate of the uptake of the first dose of mumps, measles and rubella vaccine.
    Mixer RE, Jamrozik K, Newsom D.
    J Epidemiol Community Health; 2007 Sep 31; 61(9):797-801. PubMed ID: 17699534
    [Abstract] [Full Text] [Related]

  • 30. Seroprevalence of measles, mumps and rubella antibodies in Luxembourg: results from a national cross-sectional study.
    Mossong J, Putz L, Schneider F.
    Epidemiol Infect; 2004 Jan 31; 132(1):11-8. PubMed ID: 14979584
    [Abstract] [Full Text] [Related]

  • 31. Seroprevalence of Measles, Mumps, and Rubella Antibodies in College Students in Mumbai, India.
    Gohil DJ, Kothari ST, Chaudhari AB, Gunale BK, Kulkarni PS, Deshmukh RA, Chowdhary AS.
    Viral Immunol; 2016 Apr 31; 29(3):159-63. PubMed ID: 26910764
    [Abstract] [Full Text] [Related]

  • 32. Measles, mumps, rubella prevention: how can we do better?
    Kauffmann F, Heffernan C, Meurice F, Ota MOC, Vetter V, Casabona G.
    Expert Rev Vaccines; 2021 Jul 31; 20(7):811-826. PubMed ID: 34096442
    [Abstract] [Full Text] [Related]

  • 33. Routine childhood vaccination programme coverage, El Salvador, 2011-In search of timeliness.
    Suárez-Castaneda E, Pezzoli L, Elas M, Baltrons R, Crespin-Elías EO, Pleitez OA, de Campos MI, Danovaro-Holliday MC.
    Vaccine; 2014 Jan 16; 32(4):437-44. PubMed ID: 24315884
    [Abstract] [Full Text] [Related]

  • 34. Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?
    Abbassy AA, Barakat SS, Abd El Fattah MM, Said ZN, El Metwally HA.
    East Mediterr Health J; 2009 Jan 16; 15(1):85-93. PubMed ID: 19469430
    [Abstract] [Full Text] [Related]

  • 35. Epidemiology of measles, mumps and rubella in Italy.
    Gabutti G, Rota MC, Salmaso S, Bruzzone BM, Bella A, Crovari P, Serological Study Group.
    Epidemiol Infect; 2002 Dec 16; 129(3):543-50. PubMed ID: 12558337
    [Abstract] [Full Text] [Related]

  • 36. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
    Stohrer-Draxl P, Amstad H, Grize L, Gassner M, Takken-Sahli K, Bourquin C, Braun-Fahrländer C.
    Praxis (Bern 1994); 1999 Jun 10; 88(24):1069-77. PubMed ID: 10420798
    [Abstract] [Full Text] [Related]

  • 37. Vaccines for measles, mumps, rubella, and varicella in children.
    Di Pietrantonj C, Rivetti A, Marchione P, Debalini MG, Demicheli V.
    Cochrane Database Syst Rev; 2021 Nov 22; 11(11):CD004407. PubMed ID: 34806766
    [Abstract] [Full Text] [Related]

  • 38. Introducing combined measles, mumps and rubella vaccine in Chandigarh, India: issues and concerns.
    Bhatnagar N, Kaur R, Gupta M, Sharma D.
    Indian Pediatr; 2014 Jun 22; 51(6):441-3. PubMed ID: 24986275
    [Abstract] [Full Text] [Related]

  • 39. The Immunogenicity and Safety Profile for KM-248, a Combined Measles, Mumps, and Rubella Vaccine, and Its Noninferiority to the Measles Vaccine in Healthy Japanese Children: a Phase 3 Randomized Multicenter Single-Blind Clinical Trial.
    Platt H, Tochihara S, Oda Y, Ueda K.
    Jpn J Infect Dis; 2021 Sep 22; 74(5):429-436. PubMed ID: 33518626
    [Abstract] [Full Text] [Related]

  • 40. Missed Opportunities for Measles, Mumps, Rubella Vaccination Among Departing U.S. Adult Travelers Receiving Pretravel Health Consultations.
    Hyle EP, Rao SR, Jentes ES, Parker Fiebelkorn A, Hagmann SHF, Taylor Walker A, Walensky RP, Ryan ET, LaRocque RC.
    Ann Intern Med; 2017 Jul 18; 167(2):77-84. PubMed ID: 28505632
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.